Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jane Mertens

Psychiatry Del Mar, CA Medical Doctor

NPI 1528125945 CMS profile 23223

240 9Th St, Del Mar, CA 92014

Open in the dashboard

General payments

$3,930

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jane Mertens of Del Mar, CA is reported in the CMS Open Payments database as having received $3,930 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $185 5
2024 General $344 5
2023 General $374 6
2022 General $263 8
2021 General $718 19
2020 General $783 31
2019 General $1,264 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jane Mertens
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Jane Mertens were reported at $185. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Jane Mertens Psychiatry median Middle half National median
2019 $1,264 $184 $59–$605 $163
2020 $783 $119 $36–$372 $114
2021 $718 $143 $43–$576 $132
2022 $263 $153 $50–$590 $149
2023 $374 $170 $56–$651 $160
2024 $344 $179 $57–$673 $164
2025 $185 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $1,301 35 payments
  2. Neurocrine Biosciences, Inc. $831 13 payments
  3. Lundbeck LLC $703 45 payments
  4. AbbVie, Inc. $291 5 payments
  5. Allergan Inc. $250 2 payments
  6. Axsome Therapeutics, Inc. $226 3 payments
  7. Otsuka America Pharmaceutical, Inc. $121 1 payment
  8. Alkermes, Inc. $101 1 payment
  9. Janssen Pharmaceuticals, Inc $94 1 payment
  10. Ironshore Pharmaceuticals Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,906 103 payments
  2. Education $24 4 payments
Products named General payments · program years 2019–2025
  1. LATUDA $1,301 35 payments
  2. REXULTI Psychiatry $697 42 payments
  3. INGREZZA Neuropsychiatry $431 9 payments
  4. INGREZZA Neurology $400 4 payments
  5. VRAYLAR Neuroscience $291 5 payments
  6. VRAYLAR Neuroscience $250 2 payments
  7. Auvelity $226 3 payments
  8. REXULTI Psychiatry $121 1 payment
  9. LYBALVI Cns $101 1 payment
  10. LYBALVI Cns $101 1 payment
  11. Other $314 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

344

Median for Psychiatry & Neurology: 100

Drug cost

$30,963

Median for Psychiatry & Neurology: $2,986

Branded share of claims

41.6%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 11 $17,459
Fluoxetine Dr Fluoxetine Hcl Brand 12 $2,539
Lurasidone Hcl Generic 14 $2,514
Bupropion Xl Bupropion Hcl Brand 62 $2,495
Quetiapine Fumarate Generic 33 $2,145
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 23 $650
Fluoxetine Hcl Generic 18 $632
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 18 $485
Clonazepam Generic 26 $410
Mirtazapine Generic 12 $317

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $226
$226 — —
LYBALVI
  • Alkermes, Inc. $101
$101 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record